Robert Koch Strasse 50
Mainz 55129
Germany
49 6131 554 2860
https://mainzbiomed.com
Sector(es): Healthcare
Industria: Diagnostics & Research
Empleados a tiempo completo: 65
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Guido Baechler | CEO & Executive Director | N/D | N/D | 1965 |
Mr. William J. Caragol | Chief Financial Officer | N/D | N/D | 1967 |
Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer | N/D | N/D | 1972 |
Dr. Frank Krieg-Schneider | Chief Technology Officer | N/D | N/D | 1962 |
Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director | N/D | N/D | 1984 |
Stefan Erlach | Head of Human Resources | N/D | N/D | N/D |
Mr. Philipp Freese | Chief Business Officer | N/D | N/D | 1983 |
Mr. Darin S. Leigh | Chief Commercial Officer | N/D | N/D | 1968 |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
La calificación ISS Governance QuickScore de Mainz Biomed N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.